Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan

Sato, Toshihiro; Kodama, Shinjiro; Kaneko, Keizo; Imai, Junta; Katagiri, Hideki

doi:10.3201/eid2807.220127

i

Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan

Supporting Files Public Domain

7-2022
By Sato, Toshihiro ; Kodama, Shinjiro ; Kaneko, Keizo ; ...

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Sato, Toshihiro ; Kodama, Shinjiro ; Kaneko, Keizo ; Imai, Junta ; Katagiri, Hideki
Description:

Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.
Subjects:

Covid-19 Covid-19 Vaccines Diabetes Mellitus, Type 1 Humans Immune Checkpoint Inhibitors Nivolumab Sars-Cov-2 Vaccination
Source:

Emerg Infect Dis. 2022; 28(7):1518-1520
Pubmed ID:

35468049
Pubmed Central ID:

PMC9239866
Document Type:

Letter
Place as Subject:

Japan
Volume:

28
Issue:

7
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:be4e0af57a1a54017c67eee9b26d7439934cd0d270a3b750d4f80fb43832a58d
Download URL:

https://stacks.cdc.gov/view/cdc/118929/cdc_118929_DS1.pdf
File Type:

[PDF - 328.08 KB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.